Immunohistochemical Staining and Sarcomatoid Mesothelioma: Beyond the Lab
When it comes to understanding individual cases of sarcomatoid mesothelioma, doctors should not rely too heavily on immunohistochemical staining. That conclusion comes from mesothelioma researchers at MD Anderson Cancer Center in Texas. The researchers just released a new study focused on this rare mesothelioma subtype. A patient’s subtype has an impact on what kind of treatment could work best for them. Sarcomatoid mesothelioma is usually less responsive to chemotherapy. Immunohistochemical staining is a pathology technique. It is the main way that doctors tell the difference between mesothelioma subtypes. But the MD Anderson report suggests that not all cases of sarcomatoid mesothelioma are created equal. The researchers say it is important to look beyond the lab findings to understand individual cases. … Continue reading Immunohistochemical Staining and Sarcomatoid Mesothelioma: Beyond the Lab
CRS/HIPEC Procedure Has Improved Over Time, Study Finds
A new French study contains some good news for people considering the CRS/HIPEC procedure for peritoneal mesothelioma. The CRS/HIPEC procedure combines surgical resection with localized chemotherapy. Its aim is to remove or destroy as many mesothelioma cells as possible in the abdomen. French researchers studied the evolution of the procedure over time. They discovered that it has improved. As a result, people with peritoneal cancers like malignant mesothelioma are living longer. Cytoreductive Surgery for Mesothelioma Peritoneal mesothelioma causes tumors on the peritoneal membrane that lines the abdomen. Like other forms of mesothelioma, the cause is usually asbestos exposure. Cytoreductive surgery (CRS) is an operation to remove tumors from the abdomen. Mesothelioma tumors may be confined to the peritoneal membrane, or … Continue reading CRS/HIPEC Procedure Has Improved Over Time, Study Finds
Real-World Mesothelioma Patients Need New Systemic Treatments
The newest study on real-world mesothelioma patients illustrates the need for more ways to treat this devastating cancer. Many studies focus on a carefully-chosen subset of patients. Patients have to meet specific guidelines to qualify for a mesothelioma clinical trial. But the authors of a new report in Future Oncology focused on real-world mesothelioma patients in community clinics. The goal was to see what kinds of treatments these patients got and how well they worked. The results show most people do not have other treatments after first-line therapy. They also suggest that mesothelioma doctors and patients need new first-line alternatives. First- and Second-Line Mesothelioma Therapies Malignant mesothelioma is the name for cancer on the membranes around internal organs. Pleural mesothelioma … Continue reading Real-World Mesothelioma Patients Need New Systemic Treatments
Irradiating Procedure Tracts Reduces Metastatic Mesothelioma in New Study
Irradiating the tracts through which certain interventions are performed can reduce the risk of metastatic pleural mesothelioma. That word comes from a new study in Singapore. The pleural form of malignant mesothelioma occurs on the lining around the lungs. Doctors often have to insert tools through the chest wall for diagnosis or treatment. The paths or tracts along which they insert those tools can be the site of new mesothelioma tumors. But the study shows that timely radiation treatment of those paths may prevent metastatic pleural mesothelioma. Metastatic Pleural Mesothelioma Metastasis is when cancer cells move from their original site to another place in the body. A tumor that is contained in one spot is easier to treat or remove. … Continue reading Irradiating Procedure Tracts Reduces Metastatic Mesothelioma in New Study
Age and Smoking Less Important Than Other Factors for Mesothelioma Outcomes
A newly published study suggests that a mesothelioma patient’s age and smoking history is less important to prognosis than certain biomarkers or what treatment they choose. The study comes from scientists at the National Institute of Respiratory Diseases in Mexico City. They performed a retrospective analysis of 136 patients with pleural mesothelioma. The goal was to see which factors played the biggest role in outcomes. Age and smoking were among seven factors evaluated. It turns out they were not the most important ones. Who Gets Pleural Mesothelioma? Malignant mesothelioma is the cancer most closely associated with asbestos exposure. Most people who get it have lived or worked around asbestos. Mesothelioma can take decades to develop. Most patients are over 65. … Continue reading Age and Smoking Less Important Than Other Factors for Mesothelioma Outcomes
Long-Term Mesothelioma Survival with ONCOS-102
The makers of the immunotherapy treatment ONCOS-102 have released promising new data on its ability to promote long-term mesothelioma survival. The report came less than two weeks after ONCOS-102 got FDA approval to fast-track its development. ONCOS-102 is an investigational treatment made from a modified virus. The virus helps the treatment target mesothelioma cells while leaving healthy cells alone. The new long-term mesothelioma survival data shows half of people on ONCOS-102 and chemotherapy have lived for 21 months. And the study is not over yet. Typical survival with standard mesothelioma chemotherapy is about a year. Targovax says the data shows how valuable ONCOS-102 could be for patients with this rare but aggressive malignancy. Standard of Care for Pleural Mesothelioma Pleural … Continue reading Long-Term Mesothelioma Survival with ONCOS-102
COVID-19 Vaccine May Help Mesothelioma Survivors Avoid Serious Side Effects
Several new studies illustrate the importance of the COVID-19 vaccine for malignant mesothelioma patients and survivors. They suggest that people with mesothelioma would do well to find out the rules for vaccination in their state. In one study, cancer patients who contracted the SARS-CoV-2 (COVID) infection developed serious neurologic symptoms. These symptoms are rarely seen in healthy people who get the illness. Another study showed cancer survivors were more likely to get severely ill or die from SARS-CoV-2. The study says this is because they tend to have more underlying medical conditions. An article published in Cancer Discovery found that people with cancer die of SARS-CoV-2 at a rate twice as high as those without cancer. The COVID-19 vaccine may … Continue reading COVID-19 Vaccine May Help Mesothelioma Survivors Avoid Serious Side Effects
Radiotherapy Outcomes in Mesothelioma Linked to Metabolism
Italian researchers say metabolic markers may hold the key to predicting radiotherapy outcomes in people with mesothelioma. Metabolism is the process by which cells produce energy. Metabolism is necessary for cancer cells to live. Mesothelioma cells metabolize faster than healthy cells. Radiotherapy affects cancer cell metabolism. A new study shows that compounds produced during metabolism may impact radiotherapy outcomes. It suggests that a patient’s metabolic profile – or metabolome – could help doctors choose good candidates for radiation. Radical Hemithoracic Radiotherapy and Mesothelioma Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Metabolism
Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy
Two of the most important biomarkers for pleural mesothelioma are not much help when it comes to tracking response to immunotherapy. Top mesothelioma researchers at the University of Pennsylvania drew that conclusion based on data from a cohort of 58 patients. They focused on two primary biomarkers for pleural mesothelioma: SMRP and fibulin-3. Doctors use both of these markers to diagnose and plan treatment for mesothelioma. The study confirms the correlation between these markers and mesothelioma tumor volume. But the Penn Medicine researchers say these biomarkers of pleural mesothelioma were “not useful” for measuring immunotherapy response. Understanding Biomarkers for Pleural Mesothelioma A biomarker is a substance produced by the body that indicates a biological process or condition. Most mesothelioma biomarkers … Continue reading Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy
Autoimmune Disease and Mesothelioma: Will it Impact Survival?
A new lung cancer study suggests that having an autoimmune disease will not necessarily lead to shorter cancer survival. This could be good news for pleural mesothelioma patients suffering from autoimmune disorders. Pleural mesothelioma is a lung-related disease that has many characteristics in common with lung cancer. The new study comes from Northwestern University Feinberg School of Medicine in Chicago. It included 177 lung cancer patients who also had immune diseases. Doctors compared their survival with a control group of lung cancer patients. They determined that having an autoimmune disease did not negatively impact lung cancer survival. In fact, some of those patients lived longer than those with healthy immune systems. What is an Autoimmune Disease? An autoimmune disease is … Continue reading Autoimmune Disease and Mesothelioma: Will it Impact Survival?
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!